Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease.
Masatoshi YoshimotoAkinari SekineTatsuya SuwabeYuki ObaHiroki MizunoMasayuki YamanouchiYoshifumi UbaraJunichi HoshinoNoriko InoueKiho TanakaEiko HasegawaNaoki SawaTakehiko WadaPublished in: Clinical kidney journal (2024)
In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.